Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy

B Rapoport, T Smit - Expert Opinion on Drug Safety, 2017 - Taylor & Francis
ABSTRACT Introduction: Five NK-1 RA formulations are commercially available to treat the
delayed phase of chemotherapy-induced nausea and vomiting (CINV) occurring between …
被引用次数：10 相关文章

[引用][C] Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy

B Rapoport, T Smit - Expert Opinion on Drug Safety, 2017 - cir.nii.ac.jp
Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and
vomiting associated with chemotherapy | CiNii Research CiNii 国立情報学研究所 学術情報 …

Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy

B Rapoport, T Smit - Expert opinion on drug safety, 2017 - pubmed.ncbi.nlm.nih.gov
Five NK-1 RA formulations are commercially available to treat the delayed phase of
chemotherapy-induced nausea and vomiting (CINV) occurring between days 2-5 post …

Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.

B Rapoport, T Smit - Expert Opinion on Drug Safety, 2017 - europepmc.org
Five NK-1 RA formulations are commercially available to treat the delayed phase of
chemotherapy-induced nausea and vomiting (CINV) occurring between days 2-5 post …
[PDF] academia.edu

[PDF][PDF] Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy

B Rapoport, T Smit - 2017 - academia.edu
Abstract Introduction: Five NK-1 RA formulations are commercially available to treat the
delayed phase of chemotherapy-induced nausea and vomiting (CINV) occurring between …